Background: Spondyloarthritis (SpA) is a family of chronic inflammatory disorders. Social media, such as YouTube, is a popular online platform where patients often visit for information. However, the validity of the content uploaded onto YouTube is not known.

Objectives: This study aimed to evaluate the content, reliability and quality of the most viewed English-language YouTube videos on SpA.

Methods: Keywords “spondyloarthritis”, “spondyloarthropathy” and “ankylosing spondylitis” were searched on YouTube on October 7th, 2019. The top 270 videos were screened. Videos were excluded if they were irrelevant, in non-English language or if they had no audio. Total number of views, duration on YouTube (days), video length, upload date, number of likes, dislikes, subscribers and comments were recorded for videos. A modified 5-point DISCERN tool1 and the 5-point Global Quality Scale (GQS) score2 were used to assess the reliability and quality of the videos, with higher scores indicating greater reliability and quality respectively.

Results: Two hundred of 270 videos were included in the final analysis [61.5% from healthcare professionals, 37.0% from patients, 1.5% from news channels]. Of the 200 videos, 15 were uploaded within the last year and 112 in the last five years. 120 (60%) were categorized as useful information (Group 1), 6 (3%) as misleading information (Group 2), 52 (26%) as useful patient opinion (Group 3) and 22 (11%) as misleading patient opinion (Group 4). Useful videos were mainly from healthcare professionals or patients (86%). Useful videos (Group 1 and 3) had higher median (IQR) number of subscribers [2700 (457) vs 211 (457), p < 0.01], reliability scores [3 (1) vs 2 (1), p < 0.01] and GQS scores [3 (1) vs 2 (1), p < 0.001] compared to misleading videos (Group 2 and 4), respectively.

Videos uploaded by healthcare professionals tended to have more useful information [94% vs 76% vs 66% vs 66% and 65%], and had higher median (IQR) reliability scores [3 (1) vs 2 (1), p < 0.01] and GQS scores [3 vs 2 vs 2 (1), p < 0.001] compared to patient uploaded videos respectively. Of the 5 (out of 123) videos from healthcare professionals that had misleading information, it was because of outdated information on diagnosis (3 videos) and treatment (5 videos) of SpA. Of the 22 videos that had misleading patient opinion, 9 (41%) wrongly described the clinical features for SpA and 14 (64%) portrayed the current evidence based treatment options as ineffective and described alternative treatment plans (i.e. diet restrictions, complementary and alternative medicine).

Conclusion: The majority of English language YouTube videos have useful information on the topic of SpA, however, 31% of patient opinions have inaccurate information on the clinical features and treatment options, and viewers need to be cognisant of these “fake news”.

References:

AS, as both diseases belong to the spondyloarthropathy group. 1100 patients with inflammatory rheumatic diseases provided the basis of RH-GiOP, a prospective study monitoring glucocorticoid (GC)-induced osteoporosis in patients with rheumatic diseases. RH-GiOP was established in 2015 at the Chantilly University Hospital. Bone mineral density data were measured by dual x-ray absorptiometry (DXA).

Methods: 92 patients with PsA (65% female) were compared with 51 patients suffering from AS (35% female). Potential risk and protective factors (e.g. data on GC treatment, anti-rheumatic therapy), laboratory parameters (e.g. Vitamin D, alkaline phosphatase, CRP, and inflammatory markers) and functional status (e.g. Health Assessment Questionnaire, sporting activities, back pain) were compared between these groups. Statistical analysis was performed descriptively using mean and standard deviation, t-tests for metric variables, and chi-square tests for nominal variables. Due to the heterogeneous gender distribution, an additional statistical matching was performed to compare patients matched by age and gender.

Results: Patients with PsA displayed significantly higher minimal T-scores than patients with AS (p=0.003) even though patients with AS were younger and more often male (p<0.001). AS patients showed a higher frequency of osteoporotic bone densities (p<0.05), however, no differences in the frequency of osteoporotic bone densities were found. Body-mass-index (BMI) was significantly higher (p<0.001) in PsA patients. PsA patients also showed a higher frequency of csDMARD use (p<0.001). Additional analyses among PsA patients with and without csDMARDs revealed also significantly higher minimal T-scores in PsA patients taking csDMARDs (90% Methotrexate), and both groups showed the same average of age and gender distribution. Furthermore, AS patients complained significantly more often of back pain (96 % vs. 74%, p=0.001) than PsA patients. No differences in GC use or cumulative GC dose were found. All results could be confirmed when gender results were matched and analyzed independently.

Conclusion: Our results demonstrate that patients with PsA display higher bone density compared to age and gender matched patients with ankylosing spondylitis. Possible influencing factors could be the higher frequency of csDMARD use, higher BMI or the lower frequency of back pain in PsA patients. Multivariate tests and additional biomarker investigations in larger cohorts are necessary to corroborate these findings and to identify underlying pathogenic differences which could serve for an explanation.

Disclosure of Interests: Desiree Freier: None declared, Edgar Wiebe: None declared, Robert Biesen: None declared, Thomas Buttgeriet: None declared, Sandra Hermann: None declared, Timo Gaber: None declared, Frank Buttgerit Grant/research support from: Amgen, BMS, Collantes-Estevez, GSK, Hexal, Horizon, Lilly, medica, Mundipharma, Novartis, Pfizer, Roche, and Sanofi. DOI: 10.1136/annrheumdis-2020-eular.3566

SAT0373 QUANTITATIVE ASSESSMENT OF RESPONSIVENESS IN SACROILIAC JOINTS MRI OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A PILOT STUDY.

C. Garrido-González1, M. D. C. Castro Villegas2, M. Ladehesa Pineda2, J. L. Garrido-Castro3, R. Ortega Castro4, C. González-Navas5, P. Zarco-Montejo5, R. Almodovar6, A. Bueno7, L. M. Molinero8, E. Collantes Estevez9 on behalf of SPONDYLO ARTHRITIS Study Group. 1Maimonides Biomedical Research Institute of Córdoba, Córdoba, Spain; 2Hospital Universitario Reina Sofia, Córdoba, Spain; 3Hospital Universitario Fundación Alcorcón, Madrid, Spain; 4ALCE Ingeniería, Madrid, Spain

Background: The presence of inflammatory signals in sacroiliac joints (SIJ), using MRI, is used for early diagnosis of axial spondyloarthritis (axSpA)[1]. Some studies also demonstrate that this inflammation can be suppressed quite dramatically by TNF-α blockers. Different scoring methods to quantify inflammatory changes in SIJ using MRI have been defined and validated: SPARCC, Leeds, Berlin, and ASSpMRI[4]. However, its use is complex and subjective. Recently Zarco et al[2] developed a method to measure bone marrow edema (BME) in MRI images from SIJ. This method, in a semiautomatic procedure, allows to measure the area affected by inflammation and the signal intensity to produce an index: the SCAISS. A simplified version, the s-SCAISS, using only a semi-coronal slide, has been proposed with good validity and reliability results.

Objectives: To assess responsiveness of inflammation in SIJ of axSpA patients, treated with TNF-α inhibitors, using a novel score method: the s-SCAISS.

Methods: Two rheumatologists independently quantified SIJ images from axSpA patients by three methods (s-SCAISS, SPARC and Berlin) on a single semi-coronal MRI slide (STIR). Patients were assessed before TNF-α therapy (PRE) and 3 months later (POST). Spearman correlations were used to analyze reliability among raters, Wilcoxon signed-rank test for significant differences and Cohen’s d for calculating the effect size of improvement. This shows MRI images of a patient before and after treatment.

Results: 9 axSpA patients were recruited from the COSPAR cohort (44% female, age 47±13 years, disease duration 18±14 years, BMI 29±4). Results PRE and POST are shown in Table: mean values (sd), statistical significance (NS, not significant; *, p<0.05; **, p<0.01), and Effect Size. In the first rows, different scoring system for MRI inflammation appears: Area analyzed by s-SCAISS, s-SCAISS, Berlin and SPARC (using only a semi-coronal slide). Activity and functional indexes were lower with significant differences and a large effect size. Correlations of s-SCAISS with Berlin (r=0.78; p<0.05) and SPARCC (r=0.96; p<0.001) were good; with clinical disease activity outcomes were poor, except with BASDAS (r=0.70; p<0.05). The best correlation according improvements appeared comparing reduction of ASDAS with reduction of s-SCAISS (r=0.57) but this difference was not significant. Although improvements in BASM1 was not significant, a good correlation was found between improvement in s-SCAISS and BASM1 (r=0.72; p<0.05).

SAT0374 ONSET OF AXIAL SPONDYLOARTHRITIS: REPERCUSSIONS ON PATIENTS’ SOCIAL AND FAMILY LIFE: RESULTS FROM THE EUROPEAN MAP OF AXIAL SPONDYLOARTHRITIS (EMAS).

M. Garrido-Cumbre1, 2, V. Navarro-Compañ3, C. Bundy4, R. Mahapatra5, S. Makr6, S. Sanz-Gómez7, L. Christen8, C. J. Delgado-Dominguez9, D. Podstubnýo10 on behalf of EMAS Working Group. 1Health & Territory Research (HTR), Universidad de Sevilla, Sevilla, Spain; 2Spanish Federation of Spondyloarthropathy Associations, Madrid, Spain; 3IdiPAZ, University Hospital

Conclusion: Different methods exist for quantifying inflammation in MRI images of SIJ in axSpA patients. According to our preliminary results, all of them had significant improvements in axSpA patients treated with anti-TNF-α. The s-SCAISS index show good responsiveness, with similar features to validated indexes, but with an accuracy assessment of the BME area.

Disclosure of Interests: Cristina Garrido-González: None declared, María del Carmen Castro Villegas: None declared, MLorudes Ladehesa Pineda: None declared, Juan L. Garrido-Castro: None declared, Rafaela Ortega Castro: None declared, Angel Bueno: None declared, Luis Miguel Molinero: None declared, Eduardo Collantes Estevez Grant/research support from: ROCHE and Pfizer, Speakers bureau: Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer.

References:

Disclosure of Interests: Cristina Garrido-González: None declared, María del Carmen Castro Villegas: None declared, MLorudes Ladehesa Pineda: None declared, Juan L. Garrido-Castro: None declared, Rafaela Ortega Castro: None declared, Cristina Gonzalez-Navas: None declared, Pedro Zarco-Montejo Speakers bureau: Abbvie, MSD, Novartis, Pfizer, RAQUEL ALMODOVAR Speakers bureau: Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer.

DOI: 10.1136/annrheumdis-2020-eular.2558